Skip to main content

Oncternal Therapeutics Value Stock - Dividend - Research Selection

Oncternal Therapeutics Inc

ISIN: US68236P1075, WKN: A2PL3P

Market price date: 13.01.2021
Market price: 5,09 USD




Oncternal Therapeutics Inc Fundamental data and company key figures of the share

Annual reports in USD
Key figures 16-03-2020
Cash flow
Net operating cash flow -16.746.000
Capital Expenditures -1
Free cash flow -16.746.000
Balance sheet
Total Equity 14.312.000
Liabilities & Shareholders equity 21.744.000
Income statement
Net income -34.188.000
Eps (diluted) -3,310
Diluted shares outstanding 10.329.000
Net sales/revenue 2.425.000

Fundamental ratios calculated on: 13-01-2021

Ratios
Key figures 13-01-2021
Cash flow
P/C -3,14
   
P/FC -3,14
Balance sheet
ROI-157,23
ROE65,82
Income statement
P/E-1,54
Div. Yield0,00%
P/B3,67
P/S21,68


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolONCT
Market Capitalization52.058.160,00 USD
CountryUnited States
IndicesNASDAQ Comp.
SectorsPharma
Raw Data SourceUS GAAP in Millionen USD
Stock Split2019-06-10,1.000000/7.000000; 2016-12-07,1.0000/10.0000; 2016-12-06,1.0000/10.0000
Internetwww.gtxinc.com


Description of the company

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company\'s lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.gtxinc.com